MedTrace Logo

CAVATAK® and Ipilimumab in Uveal Melanoma Metastatic to the Liver (VLA-024 CLEVER)

NCT03408587 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2023-05-06

No results posted yet for this study

Summary

This is an open-label Phase 1b clinical study of ipilimumab in combination with intravenous CVA21 in subjects who have uveal melanoma metastatic to liver.

Conditions

Interventions

BIOLOGICAL

CVA21

Oncolytic virus

BIOLOGICAL

Ipilimumab

Fully human IgG1 monoclonal antibody that binds to the CTLA-4 receptor expressed on activated T cells.

Sponsors & Collaborators

  • Viralytics

    lead INDUSTRY

Principal Investigators

  • Jose Lutzky, MD · Icahn School of Medicine at Mount Sinai

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-29
Primary Completion
2019-05-22
Completion
2019-05-22
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03408587 on ClinicalTrials.gov